Compare Johnson & Johnson (JNJ) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Virgin Galactic Holdings, Inc. — how do they compare? Johnson & Johnson trades at $261.41 (market cap $618.09B), while Virgin Galactic Holdings, Inc. trades at $2.86 (market cap $445.69M). The key difference: Johnson & Johnson is far larger — about 1386.8× Virgin Galactic Holdings, Inc.'s market cap, and Johnson & Johnson pays a 2.09% dividend while Virgin Galactic Holdings, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Virgin Galactic Holdings, Inc. for 69 Days on average.
| JNJ | SPCE | |
|---|---|---|
Market Cap | $618.09B | $445.69M |
Volume | 6,050,983 | 5,128,850 |
Sector | Health | Industrials |
52-Week High | $278.43 | $7.52 |
52-Week Low | $186.00 | $2.17 |
Typical Hold Time | 129 Days | 69 Days |
Enterprise Value | $646.37B | $409.68M |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
Virgin Galactic (SPCE) trades at $2.84, down 5.65% on the day, reflecting ongoing volatility amid a bearish technical signal. The company continues to report significant losses with a net income margin of -23,867.44% (2025 financials), though it has beaten EPS estimates in recent quarters. Cash flow remains negative, but the trend is improving, with management targeting positive quarterly cash flow by 2027. Recent news highlights strong ticket demand but also a delay in commercial Delta flights to February 2027.
The outlook remains high-risk due to persistent losses and cash burn, but long-term potential exists in commercial spaceflight. Investment opportunity hinges on successful execution of the Delta program and achieving profitability targets. Key risks include execution delays, high cash burn, competitive pressures, and stock dilution. Analyst sentiment is mixed, with 29.41% buy ratings, reflecting cautious optimism amid substantial operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →
